Your browser doesn't support javascript.
loading
Apatinib for the treatment of gastric cancer.
Roviello, Giandomenico; Ravelli, Andrea; Fiaschi, Anna Ida; Cappelletti, Maria Rosa; Gobbi, Angela; Senti, Chiara; Zanotti, Laura; Polom, Karol; Reynolds, Andrew R; Fox, Stephen B; Generali, Daniele.
Afiliación
  • Roviello G; a Department of Molecular and Translational Medicine , University of Brescia , Brescia , Italy.
  • Ravelli A; b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
  • Fiaschi AI; c Section of Experimental Oncology, Department of Clinical and Experimental Medicine , University of Parma , Parma , Italy.
  • Cappelletti MR; d Pharmacology Unit , University of Siena , Siena , Italy.
  • Gobbi A; b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
  • Senti C; b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
  • Zanotti L; b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
  • Polom K; b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.
  • Reynolds AR; e Department of Medical, Surgical and Neuroscience; Unit of General and Minimally Invasive Surgery , University of Siena , Siena , Italy.
  • Fox SB; f Tumour Biology Team, Breast Cancer Now Research Centre , The Institute of Cancer Research , London , UK.
  • Generali D; g Department of Pathology, Peter Mac Callum Cancer Centre, Department of Pathology , University of Melbourne , Melbourne , Australia.
Expert Rev Gastroenterol Hepatol ; 10(8): 887-92, 2016 Aug.
Article en En | MEDLINE | ID: mdl-27376400
ABSTRACT

INTRODUCTION:

Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models. AREAS COVERED Apatinib's efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer. Expert commentary Unfortunately, as yet, there is no definitive biomarker data for apatinib in gastric cancer.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridinas / Neoplasias Gástricas / Inhibidores de la Angiogénesis / Receptor 2 de Factores de Crecimiento Endotelial Vascular / Inhibidores de Proteínas Quinasas / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Expert Rev Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Piridinas / Neoplasias Gástricas / Inhibidores de la Angiogénesis / Receptor 2 de Factores de Crecimiento Endotelial Vascular / Inhibidores de Proteínas Quinasas / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Expert Rev Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2016 Tipo del documento: Article País de afiliación: Italia